價(jià)格 | 詢價(jià) |
包裝 | 25Kg/Drum |
最小起訂量 | 25Kg |
發(fā)貨地 | 湖北 |
更新日期 | 2020-11-10 |
中文名稱:硝酸異山梨酯 | 英文名稱:Isosorbide Dinitrate |
CAS:87-33-2 | 產(chǎn)品類別: boshan |
isosorbide dinitrate structure
|
Common Name | isosorbide dinitrate | ||
---|---|---|---|---|
CAS Number | 87-33-2 | Molecular Weight | 236.136 | |
Density | 1.7±0.1 g/cm3 | Boiling Point | 365.9±42.0 °C at 760 mmHg | |
Molecular Formula | C6H8N2O8 | Melting Point | 700C | |
MSDS | N/A | Flash Point | 186.6±29.9 °C | |
Symbol | GHS07 |
Signal Word |
Warning
|
Description | Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI)[1]. |
---|---|
Related Catalog |
Research Areas >> Cardiovascular Disease
Signaling Pathways >> Immunology/Inflammation >> NO Synthase
|
In Vivo | Isosorbide dinitrate (3 mg/kg; intratracheal; for 13 days) improves pulmonary artery pressure and ventricular remodeling in a rat model of heart failure following myocardial infarction[1]. Isosorbide dinitrate postconditioning exhibits a cardioprotective effect against rat myocardial ischemia-reperfusion injury in vivo[2]. Animal Model: 5–6 weeks old male juvenile Sprague-Dawley rats (200–250 g)[1] Dosage: 3 mg/kg Administration: Intratracheal; for 13 days following coronary ligation Result: Reduced MI size and alleviated left and right ventricular remodeling following MI. |
References |
[1]. Wang X , et al. Intratracheal administration of isosorbide dinitrate improves pulmonary artery pressure and ventricular remodeling in a rat model of heart failure following myocardial infarction. Exp Ther Med. 2017 Aug;14(2):1399-1408. [2]. Zhao X, et al. Cardioprotective Effect of Isosorbide Dinitrate Postconditioning Against Rat Myocardial Ischemia-Reperfusion Injury In Vivo. Med Sci Monit. 2019 Mar 2;25:1629-1636. |
Density | 1.7±0.1 g/cm3 |
---|---|
Boiling Point | 365.9±42.0 °C at 760 mmHg |
Melting Point | 700C |
Molecular Formula | C6H8N2O8 |
Molecular Weight | 236.136 |
Flash Point | 186.6±29.9 °C |
Exact Mass | 236.028061 |
PSA | 128.56000 |
LogP | 0.90 |
Vapour Pressure | 0.0±0.8 mmHg at 25°C |
Index of Refraction | 1.538 |
Symbol | GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H302 |
Precautionary Statements | P301 + P312 + P330 |
Hazard Codes | Xn:Harmful; |
Risk Phrases | R5;R22 |
Safety Phrases | S36 |
RIDADR | UN 2907 |
Packaging Group | II |
Hazard Class | 1.1A |
HS Code | 3004909090 |
Isosorbide CAS#:652-67-5 ~91% isosorbide dinitrate CAS#:87-33-2 |
Literature: Bhar, Debjani; Chandrasekaran, Srinivasan Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1997 , vol. 36, # 9 p. 793 - 795 |
Precursor 1 |
|
---|---|
DownStream 2 |
|
CONTACT
- Liu Zhihao
- Tel & WhatsApp : +86 15972591113
- QQ & WeChat: 577507723
- Skype : smile491012
成立日期 | 1999-03-09 (26年) | 注冊(cè)資本 | 1877663513 |
員工人數(shù) | 500人以上 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 醫(yī)藥中間體,原料藥,獸藥原料,維生素類 | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP3年
|
湖北興琰新材料科技有限公司
|
2024-11-16 | |
詢價(jià) |
VIP5年
|
武漢克米克生物醫(yī)藥技術(shù)有限公司
|
2024-11-16 | |
詢價(jià) |
VIP3年
|
普善實(shí)業(yè)(陜西)有限公司
|
2024-11-15 | |
詢價(jià) |
VIP6年
|
湖北阡陌生物科技有限公司
|
2024-11-15 | |
詢價(jià) |
VIP3年
|
貝彩化學(xué)
|
2024-11-14 | |
詢價(jià) |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2024-11-13 | |
詢價(jià) |
VIP4年
|
陜西締都醫(yī)藥化工有限公司
|
2024-11-13 | |
詢價(jià) |
VIP4年
|
湖北辰心藥業(yè)有限公司
|
2024-11-11 | |
詢價(jià) |
中國(guó)食品藥品檢定研究院
|
2024-11-05 | ||
¥2000 |
VIP7年
|
湖北帝柏化工有限公司
|
2024-11-04 |